Definium Therapeutics, Inc. Common Shares (DFTX) Stock Price
DFTXStock
$32.10+169.52%52W
Market Cap$4.31B
P/E—
PEG Ratio—
Div yield—
Beta2.26
DFTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)36.47%
Price vs S&P 500 (4W)-16.95%
VGM Score66.75
DFTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.55 | -$1.44 | -162.25%(-$0.89) | |
| Q1 2026 | -$0.49 | -$0.71 | -44.02%(-$0.22) | |
| Q4 2025 | -$0.49 | -$0.50 | -2.04%(-$0.01) | |
| Q3 2025 | -$0.50 | -$0.78 | -54.84%(-$0.28) | |
| Q2 2025 | -$0.36 | -$0.50 | -38.34%(-$0.14) |
DFTX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.32
4.32
4.30
4.33
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
DFTXDefinium Therapeutics, Inc. Common Shares | — | — | B | — | — | — | — | $32.10 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | B | — | — | — | — | $9.59 |
| TRLVTrulieve Cannabis Corp. | B | C | A | 1.7x | -3.9% | 59.5% | — | $10.01 |
| CRONCronos Group Inc. Common Share | C | B | A | 6.6x | 37.5% | 46.5% | -50.0% | $3.21 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | 0.5x | 15.9% | 29.1% | — | $3.04 |
| CGCCanopy Growth Corporation Common Shares | B | C | D | 1.6x | 6.8% | 28.5% | — | $0.71 |
| SNDLSundial Growers Inc. Common Shares | B | C | B | 0.5x | -1.7% | 26.2% | — | $1.25 |
| GLASGlass House Brands Inc. | B | C | D | 1.2x | -25.6% | 30.8% | — | $3.19 |
| USNAUSANA Health Sciences Inc | B | D | C | 0.3x | 5.7% | 77.5% | -37.0% | $15.54 |
| ACBAurora Cannabis Inc. Common Shares | B | D | B | 1.3x | -18.9% | 6.3% | — | $3.99 |
| NAGENiagen Bioscience, Inc. Common Stock | C | C | D | 1.5x | 11.0% | 64.2% | — | $2.49 |
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics develops novel therapeutics targeting the underlying causes of psychiatric and neurological disorders, aiming for long-term patient remission rather than symptom management. Its pipeline includes four Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), led by DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. The company is advancing commercial and operational readiness ahead of potential product launch.